

Remarks

In response to the Office Action requiring restriction under 35 U.S.C. 121, applicants elect for prosecution at this time the claims of Group I, i.e., claims 1-10 and 32 drawn to a DNA vaccine.

For examination with the subject matter of Group I applicants elect the polypeptide of SEQ ID NO: 6 and the corresponding polynucleotide of SEQ ID NO: 5.

The foregoing elections are made without traverse.

Dependent claims 33 and 34, drawn to the elected polypeptide sequence and the elected polynucleotide sequence, respectively, have been added. Thus Group I is now constituted by claims 1-10 and 32-34, inclusive.


Non-elected claims 11-31, inclusive, are canceled without prejudice in favor of a divisional application.

In view of the cancellation of claims 11-31 no additional claim fees are deemed to be due at this time.

An early action on the merits is solicited.

Respectfully submitted,

June 2, 2004

By 
Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & HIERL, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180